{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:48:00Z","timestamp":1760550480723,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.vaccine.2018.01.041","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T21:37:23Z","timestamp":1517607443000},"page":"1167-1173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of a high-growth enterovirus 71 vaccine candidate inducing cross-reactive neutralizing antibody responses"],"prefix":"10.1016","volume":"36","author":[{"given":"Min-Yuan","family":"Chia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Yu","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Hsiung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Hau","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Shi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.01.041_b0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0168-1702(95)00087-9","article-title":"Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus","volume":"39","author":"Brown","year":"1995","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.01.041_b0010","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1473-3099(10)70194-8","article-title":"Virology, epidemiology, pathogenesis, and control of enterovirus 71","volume":"10","author":"Solomon","year":"2010","journal-title":"Lancet Infec Dis"},{"key":"10.1016\/j.vaccine.2018.01.041_b0015","doi-asserted-by":"crossref","first-page":"e3044","DOI":"10.1371\/journal.pntd.0003044","article-title":"Monitoring antigenic variations of enterovirus 71: implications for virus surveillance and vaccine development","volume":"8","author":"Chia","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.01.041_b0020","doi-asserted-by":"crossref","first-page":"e20005","DOI":"10.1371\/journal.pone.0020005","article-title":"Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.01.041_b0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1586\/erv.09.152","article-title":"Development of enterovirus 71 vaccines","volume":"9","author":"Lee","year":"2010","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2018.01.041_b0030","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/infdis\/129.3.304","article-title":"An apparently new enterovirus isolated from patients with disease of the central nervous system","volume":"129","author":"Schmidt","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.041_b0035","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/cid\/ciu852","article-title":"Review of enterovirus 71 vaccines","volume":"60","author":"Chong","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.041_b0040","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1038\/emi.2016.101","article-title":"Molecular epidemiology of human enterovirus 71 at the origin of an epidemic of fatal hand, foot and mouth disease cases in Cambodia","volume":"5","author":"Duong","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2018.01.041_b0045","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3201\/eid1811.111457","article-title":"Antigenic diversity of enteroviruses associated with nonpolio acute flaccid paralysis, India, 2007\u20132009","volume":"18","author":"Rao","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.041_b0050","doi-asserted-by":"crossref","first-page":"e90624","DOI":"10.1371\/journal.pone.0090624","article-title":"Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity","volume":"9","author":"Bessaud","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.01.041_b0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3201\/eid2101.140743","article-title":"Genetic diversity of enterovirus A71 India","volume":"21","author":"Saxena","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.041_b0060","doi-asserted-by":"crossref","first-page":"e1737","DOI":"10.1371\/journal.pntd.0001737","article-title":"Challenges to licensure of enterovirus 71 vaccines","volume":"6","author":"Lee","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.01.041_b0065","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pedneo.2013.07.007","article-title":"Epidemiology of enterovirus 71 infections in Taiwan","volume":"55","author":"Chia","year":"2014","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.vaccine.2018.01.041_b0070","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1086\/511073","article-title":"Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study","volume":"44","author":"Ooi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.041_b0075","doi-asserted-by":"crossref","first-page":"e0116322","DOI":"10.1371\/journal.pone.0116322","article-title":"Reemergence of enterovirus 71 epidemic in northern Taiwan, 2012","volume":"10","author":"Luo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.01.041_b0080","doi-asserted-by":"crossref","first-page":"e69895","DOI":"10.1371\/journal.pone.0069895","article-title":"Genetic and antigenic characterization of enterovirus 71 in Ho Chi Minh City, Vietnam, 2011","volume":"8","author":"Thoa le","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.01.041_b0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.virusres.2009.06.006","article-title":"Appearance of mosaic enterovirus 71 in the 2008 outbreak of China","volume":"145","author":"Ding","year":"2009","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.01.041_b0090","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/JVI.80.1.483-493.2006","article-title":"Frequency and dynamics of recombination within different species of human enteroviruses","volume":"80","author":"Simmonds","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.041_b0095","doi-asserted-by":"crossref","first-page":"19780","DOI":"10.3402\/ehtj.v6i0.19780","article-title":"Human enterovirus 71 epidemics: what's next?","volume":"6","author":"Yip","year":"2013","journal-title":"Emerg Health Threats"},{"key":"10.1016\/j.vaccine.2018.01.041_b0100","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1128\/JCM.00630-09","article-title":"Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008","volume":"47","author":"Huang","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.01.041_b0105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/1743-422X-7-277","article-title":"Genetic diversity and C2-like subgenogroup strains of enterovirus 71, Taiwan, 2008","volume":"7","author":"Huang","year":"2010","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2018.01.041_b0110","doi-asserted-by":"crossref","first-page":"e2067","DOI":"10.1371\/journal.pntd.0002067","article-title":"Cross-reactive neutralizing antibody responses to enterovirus 71 infections in young children: implications for vaccine development","volume":"7","author":"Huang","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.01.041_b0115","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1128\/JVI.02035-15","article-title":"Mapping enterovirus A71 antigenic determinants from viral evolution","volume":"89","author":"Huang","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.041_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11262-010-0472-9","article-title":"Genetic analysis of the VP1 region of enterovirus 71 reveals the emergence of genotype A in central China in 2008","volume":"41","author":"Yu","year":"2010","journal-title":"Virus Genes"},{"key":"10.1016\/j.vaccine.2018.01.041_b0125","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0264-410X(98)80025-X","article-title":"Surveillance of suspected poliomyelitis in Albania, 1980\u20131995: suggestion of increased risk of vaccine associated poliomyelitis","volume":"16","author":"Diamanti","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.041_b0130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/JVI.00999-09","article-title":"Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease","volume":"84","author":"Ong","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.041_b0135","doi-asserted-by":"crossref","first-page":"e79783","DOI":"10.1371\/journal.pone.0079783","article-title":"Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers","volume":"8","author":"Chou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.01.041_b0140","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.vaccine.2011.11.087","article-title":"Selection and characterization of vaccine strain for Enterovirus 71 vaccine development","volume":"30","author":"Chang","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.041_b0145","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.4161\/hv.21739","article-title":"Production of EV71 vaccine candidates","volume":"8","author":"Chong","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.01.041_b0150","doi-asserted-by":"crossref","first-page":"e24057","DOI":"10.1371\/journal.pone.0024057","article-title":"Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness","volume":"6","author":"Tseng","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.01.041_b0155","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/S0264-410X(02)00182-2","article-title":"Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate","volume":"20","author":"Lin","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.041_b0160","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1099\/0022-1317-51-1-147","article-title":"The preparation of specific immune sera against type 3 poliovirus D-antigen and C-antigen and the demonstration of two C-antigenic components in vaccine strain populations","volume":"51","author":"Minor","year":"1980","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.01.041_b0165","doi-asserted-by":"crossref","first-page":"e0136420","DOI":"10.1371\/journal.pone.0136420","article-title":"Inactivated Enterovirus 71 vaccine produced by 200-L scale serum-free microcarrier bioreactor system provides cross-protective efficacy in human SCARB2 transgenic mouse","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.01.041_b0170","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/erv.09.19","article-title":"Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines","volume":"8","author":"Barrett","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.01.041_b0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/104063879801000203","article-title":"Prevalence of bovine viral diarrhea virus genotypes and antibody against those viral genotypes in fetal bovine serum","volume":"10","author":"Bolin","year":"1998","journal-title":"J Vet Diagn Invest"},{"key":"10.1016\/j.vaccine.2018.01.041_b0180","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1128\/JVI.80.1.172-180.2006","article-title":"Characterization of early steps in the poliovirus infection process: receptor-decorated liposomes induce conversion of the virus to membrane-anchored entry-intermediate particles","volume":"80","author":"Tuthill","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.041_b0185","doi-asserted-by":"crossref","first-page":"e1003240","DOI":"10.1371\/journal.ppat.1003240","article-title":"The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating","volume":"9","author":"Shingler","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.01.041_b0190","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1128\/jvi.71.12.9743-9752.1997","article-title":"Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus","volume":"71","author":"Curry","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.041_b0195","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1128\/jvi.69.3.1540-1547.1995","article-title":"Amino acid substitutions in the poliovirus maturation cleavage site affect assembly and result in accumulation of provirions","volume":"69","author":"Ansardi","year":"1995","journal-title":"J Virol"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2018.01.041_b0200","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1099\/0022-1317-71-6-1271","article-title":"Differences in conformation of type 3 poliovirus antigenic sites on non-infectious empty particles and infectious virus","volume":"71","author":"Ferguson","year":"1990","journal-title":"J Gen Virol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.01.041_b0205","doi-asserted-by":"crossref","first-page":"S345","DOI":"10.1093\/clinids\/6.Supplement_2.S345","article-title":"Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd","volume":"6","author":"Von Seefried","year":"1984","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.041_b0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/1045-1056(95)90017-9","article-title":"A WHO Collaborative study on assays of the antigenic content of inactivated poliovirus vaccines","volume":"23","author":"Wood","year":"1995","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2018.01.041_b0215","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7150\/thno.7457","article-title":"Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop","volume":"4","author":"Xu","year":"2014","journal-title":"Theranostics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:24:33Z","timestamp":1759400673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18300902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0264410X18300902"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.041","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a high-growth enterovirus 71 vaccine candidate inducing cross-reactive neutralizing antibody responses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}